Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes

Area of Science:

• Microbiology
• Endocrinology
• Metabolic Disorders

Background:

• Gut microbiota influences host metabolism, immunity, and behavior.
• Diet shapes gut microbiota, leading to Short Chain Fatty Acid (SCFA) production.
• Pancreatic dysfunction and Type 2 Diabetes (T2D) involve impaired insulin-glucagon balance and hyperglycemia.

Purpose of the Study:

• To explore the potential therapeutic role of SCFAs in pancreatic dysfunction and T2D.
• To investigate the link between SCFA production and Glucagon-like peptide-1 (GLP1) secretion.
• To highlight a novel treatment avenue for metabolic disorders.

Main Methods:

• Literature review of studies on gut microbiota, SCFAs, GLP1, and pancreatic function.
• Analysis of the mechanisms by which SCFAs influence host metabolism.
• Synthesis of current knowledge on SCFA-mediated GLP1 regulation.

Main Results:

• SCFAs, primarily acetate, propionate, and butyrate, are fermentation products of gut microbiota.
• SCFAs are known to stimulate the production of Glucagon-like peptide-1 (GLP1).
• The direct impact of SCFAs on pancreatic dysfunction remains under-investigated.

Conclusions:

• SCFAs represent a promising, yet underexplored, therapeutic target for pancreatic dysfunction and T2D.
• Further research is warranted to elucidate the direct effects of SCFAs on pancreatic islets and glucose homeostasis.
• Targeting gut microbiota fermentation could offer a novel strategy for managing T2D.